Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo

Nature Medicine

Volumn 6, Issue 7, 2000, Pages 762-768

  Chapuis, Aude G ^a   Rizzardi, G Paolo ^a   D'Agostino, Claudia ^a   Attinger, Antoine ^b   Knabenhans, Christian ^a   Fleury, Sylvain ^a   Acha Orbea, Hans ^b   Pantaleo, Giuseppe ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GUANOSINE; KI 67 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHYTOHEMAGGLUTININ; RNA DIRECTED DNA POLYMERASE;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MYCOPHENOLIC ACID; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0033942250     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/77489     Document Type: Article

References (49)

1. Deeks, S.C., Smith, M., Holodniy, M. & Kahn, J.O. HIV-1 protease inhibitors. A review for clinicians. J. Am. Med. Assoc. 277, 145-153 (1997).
2. Gulick, R.M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
3. Hammer, S.M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N. Engl. J. Med. 337, 725-733 (1997).
4. Flexner, C. HIV-protease inhibitors. N. Engl. J. Med. 338, 1281-1292 (1998).
5. Palella, F.J.J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860 (1998).
6. Montaner, J.S., Hogg, R., Raboud, J., Harrigan, R. & O'Shaughnessy, M. Antiretroviral treatment in 1998. Lancet 352, 1919-1922 (1998).
7. Cavert, W. et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964 (1997).
8. Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
9. Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
10. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
11. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
12. Yearly, S. et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS 14 (2000).
13. Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1663-1668 (1999).
14. Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
15. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
16. Pantaleo, G. How immune-based interventions can change HIV therapy. Nature Med. 3, 483-486 (1997).
17. Lori, F. et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266, 801-805 (1994).
18. Gao, W.Y., Johns, D.G. & Mitsuya, H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3⊄-dideoxynudeosides. Mol. Pharmacol. 46, 767-772 (1994).
19. Allison, A.C., Almquist, S.J., Muller, C.D. & Eugui, E.M. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc. 23, 10-14 (1991).
20. Allison, A.C., Kowalski, W.J., Muller, C.D. & Eugui, E.M. Mechanisms of action of mycophenolic acid. Ann. NY Acad. Sci. 696, 63-87 (1993).
21. Margolis, D. et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. Acquir. Immune Defic. Syndr. 21, 362-370 (1999).
22. Fulton, B. & Markham, A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51, 278-298 (1996).
23. Ichimura, H. & Levy, J.A. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 211, 554-560 (1995).
24. Blaak, H., Brouwer, M., Ran, L.J., de Wolf, F. & Schuitemaker, H. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177, 600-610 (1998).
25. Eugui, E.M., Almquist, S.J., Muller, C.D. & Allison, A.C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand. J Immunol. 33, 161-173 (1991).
26. Eugui, E.M., Mirkovich, A. & Allison, A.C. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand. J. Immunol. 33, 175-183 (1991); erratum: 48, 45 (1998).
27. Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Meth. 184, 39-51 (1995).
28. Martin, S.J. et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182, 1545-1556 (1995).
29. Schejter, E.D. & Wieschaus, E. Bottleneck acts as a regulator of the microfilament network governing cellularization of the Drosophila embryo. Cell 75, 373-385 (1993).
30. Hirons, G.T., Fawcett, J.J. & Crissman, H.A. TOTO and YOYO: new very bright fluorochromes for DNA content analyses by flow cytometry. Cytometry 15, 129-140 (1994).
31. European Mycophenolate Mofetil Cooperative Study, G. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345, 1321-1325 (1995).
32. Halloran, P. et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The international mycophenolate mofetil renal transplant study groups. Transplantation 63, 39-47 (1997); erratum: 63, 618 (1997).
33. Fleury, S. et al. Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active anti-retroviral therapy. Nature Med. 4, 794-801 (1998).
34. Fleury, S. et al. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97, 5393-5398 (2000).
35. Hellerstein, M. et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Med 5, 83-89 (1999).
36. Hellerstein, M.K. Measurement of T-cell kinetics: recent methodologic advances. Immunol. Today 20, 438-441 (1999).
37. de Jong, M.D. et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc. Natl. Acad. Sci USA 93, 5501-5506 (1996).
38. De Boer, R.J., Boucher, C.A. & Perelson, A.S. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 12, 1567-1570 (1998).
39. Zack, J.A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
40. Zhang, Z. et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4(+) T cells. Science 286, 1353-1357 (1999).
41. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
42. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science 278, 1295-1300 (1997).
43. Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci U.S.A. 94, 13193-13197 (1997).
44. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
45. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
46. Rutschmann, O.T. et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV cohort study. AIDS 12, F71-77 (1998).
47. Cantrell, D.A. & Smith, K.A. The interleukin-2 T-cell system: a new cell growth model. Science 224, 1312-1316 (1984).
48. Myers, L.E., McQuay, L.J. & Hollinger, F.B. Dilution assay statistics. J. Clin. Microbiol. 32, 732-739 (1994).
49. Chun, T.W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).